ProCE Banner Activity

INSIGHT: Wk 24 Efficacy, Safety, and PK of BIC/FTC/TAF in Adults Living With HIV and Tuberculosis Receiving Rifampicin

Conference Coverage

In this phase IIb study of patients living with HIV and TB receiving rifampicin, BIC/FTC/TAF dosed twice daily safely and effectively suppressed HIV-1 RNA without treatment failures at 24 weeks after ART initiation.

Released: March 08, 2024


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


This activity is supported through independent educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare